MetaVia Inc. (NASDAQ:MTVA) Short Interest Up 82.9% in February

MetaVia Inc. (NASDAQ:MTVA) saw a significant growth in short interest in February. As of February 27th, there was short interest totaling 102,676 shares, a growth of 82.9% from the February 12th total of 56,146 shares. Based on an average daily volume of 131,429 shares, the short-interest ratio is currently 0.8 days. Approximately 4.7% of the shares of the stock are short sold. Approximately 4.7% of the shares of the stock are short sold. Based on an average daily volume of 131,429 shares, the short-interest ratio is currently 0.8 days.

Hedge Funds Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC purchased a new stake in MetaVia Inc. (NASDAQ:MTVA) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia at the end of the most recent reporting period. Hedge funds and other institutional investors own 1.37% of the company’s stock.

Analyst Upgrades and Downgrades

MTVA has been the subject of several research analyst reports. HC Wainwright boosted their price objective on shares of MetaVia from $12.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Finally, Wall Street Zen cut MetaVia from a “hold” rating to a “sell” rating in a research note on Saturday, January 31st. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $36.50.

MetaVia Trading Down 1.2%

NASDAQ:MTVA opened at $1.61 on Friday. MetaVia has a 1 year low of $1.34 and a 1 year high of $23.10. The stock has a 50-day moving average price of $3.08 and a two-hundred day moving average price of $7.24. The stock has a market cap of $3.54 million, a price-to-earnings ratio of -0.19 and a beta of 0.33.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.